Update on a real-world study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

Alghazali, Mohammed; Löfgren, Annica; Cheng, Newton; Fagerlund, Karin; Bjartell, Anders

Alghazali, Mohammed; Löfgren, Annica; Cheng, Newton; Fagerlund, Karin; Bjartell, Anders.

Afiliação

Alghazali M; Department of Urology, Skåne University Hospital, Malmö, Sweden.
Löfgren A; Department of Urology, Skåne University Hospital, Malmö, Sweden.
Cheng N; IQVIA Solutions a/s, Copenhagen, Denmark.
Fagerlund K; Astellas Pharma a/s - Nordic Operation, Kastrup, Denmark.
Bjartell A; Department of Urology, Skåne University Hospital, Malmö, Sweden.

Scand J Urol ; 54(3): 263-264, 2020 06.

Article em En | MEDLINE | ID: mdl-32285739

Assuntos

Neoplasias de Próstata Resistentes à Castração; Benzamidas; Duração da Terapia; Humanos; Masculino; Nitrilas; Feniltioidantoína/análogos & derivados; Sistema de Registros; Suécia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Limite: Humans / Male País como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google